ライフサイエンスコーパス: vaccine efficacy

1 is reduced by a factor that is equal to the vaccine efficacy).

2 ovar Salmonella enterica serovar Dublin (85% vaccine efficacy).

3 a (1951 infections) (P=0.04 for differential vaccine efficacy).

4 Tcm/Tem cell ratio is essential for optimal vaccine efficacy.

5 regions of the glycoprotein does not enhance vaccine efficacy.

6 rks in influencing antimalarial immunity and vaccine efficacy.

7 tailored adjuvants could potentially improve vaccine efficacy.

8 oader impact of immunoregulatory networks on vaccine efficacy.

9 inistering Ag at this checkpoint may improve vaccine efficacy.

10 sting that 2 and 3 doses may have comparable vaccine efficacy.

11 l expansion, which in turn provides improved vaccine efficacy.

12 ehicle is a promising strategy for enhancing vaccine efficacy.

13 ns regarding the impact of HCMV infection on vaccine efficacy.

14 ertoire response that was associated with no vaccine efficacy.

15 ion of neuraminidase (NA) to influenza virus vaccine efficacy.

16 ctive nitrogen species was not necessary for vaccine efficacy.

17 nd inducible nitric oxide synthase (iNOS) to vaccine efficacy.

18 n mechanisms of whooping cough infection and vaccine efficacy.

19 ected by altered immunogenicity and possibly vaccine efficacy.

20 ut for these mutants, which could compromise vaccine efficacy.

21 no evidence of differential allele-specific vaccine efficacy.

22 nses generally correlate with protection and vaccine efficacy.

23 termines postvaccination serum Ab levels and vaccine efficacy.

24 learance compared to controls, demonstrating vaccine efficacy.

25 influenza vaccination will aid in maximizing vaccine efficacy.

26 osing, and schedule, as well as to establish vaccine efficacy.

27 feasible therapeutic strategy to improve DC vaccine efficacy.

28 as been proposed as a candidate mechanism of vaccine efficacy.

29 rus challenge of animals is used to evaluate vaccine efficacy.

30 and CD8alpha(+) DCs has no adverse effect on vaccine efficacy.

31 n RV genotypes, plausibly leading to reduced vaccine efficacy.

32 rly individuals results in reduced influenza vaccine efficacy.

33 ls and Tregs during BCG vaccination promotes vaccine efficacy.

34 responses in aged individuals for increased vaccine efficacy.

35 hancing antitumor immune response and cancer vaccine efficacy.

36 the association of a class I HLA allele and vaccine efficacy.

37 sess the impact of the immunization route on vaccine efficacy.

38 during BCG vaccination dramatically improves vaccine efficacy.

39 the quality of antibody responses to improve vaccine efficacy.

40 ates in these animals to potentially improve vaccine efficacy.

41 ircumvent this evasion strategy and increase vaccine efficacy.

42 , robust T cell responses could enhance ZIKV vaccine efficacy.

43 lications of these results for understanding vaccine efficacy.

44 B/subtype E (B/E) proteins demonstrated 31% vaccine efficacy.

45 N) junction or deletion of PIV5 SH increased vaccine efficacy.

46 novel approach in determining mechanisms of vaccine efficacy.

47 nfection following immunization and augments vaccine efficacy.

48 e framework for understanding and evaluating vaccine efficacy.

49 ver, there are limited data validating their vaccine efficacy.

50 l centres (GCs) promote humoral immunity and vaccine efficacy.

51 but similar anti-infectivity may not improve vaccine efficacy.

52 onses, and LATS1/2 deficiency enhances tumor vaccine efficacy.

53 y (January-June 2015), vaccine coverage, and vaccine efficacy.

54 ity, potency of therapeutic intervention and vaccine efficacy.

55 ine-induced CD4(+) cells in cross-protective vaccine efficacy.

56 ovide insights to overcome bottlenecks in TB vaccine efficacy.

57 for immuno-monitoring and could help predict vaccines efficacy.

58 can the IFN response be harnessed to improve vaccine efficacy?

59 or predictive models of viral adaptation and vaccine efficacy?

60 group had moderate or severe ETEC diarrhoea (vaccine efficacy 34.6%, -2.2 to 58.9; p=0.0621).

61 eat analysis, similar efficacy was observed (vaccine efficacy, 37.7%, 41.1%, and 75.8%, respectively)

62 3 group and 60 persons in the placebo group (vaccine efficacy, 45.0%; 95.2% CI, 14.2 to 65.3), and in

63 3 group and 90 persons in the placebo group (vaccine efficacy, 45.6%; 95.2% confidence interval [CI],

64 CV13 group and 787 persons in placebo group (vaccine efficacy, 5.1%; 95% CI, -5.1 to 14.2).

65 3 group and 28 persons in the placebo group (vaccine efficacy, 75.0%; 95% CI, 41.4 to 90.8).

66 ) and 4 of 33 (12.1%) vaccinees at 3 months (vaccine efficacy, 79.5%; P < .0001).

67 ut only 2 of 35 (5.7%) vaccinees at 10 days (vaccine efficacy, 90.3%; P < .0001) and 4 of 33 (12.1%)

68 uvant candidate that can be used to increase vaccine efficacy, a pressing issue in children and the e

69 ce maps of vaccination rates and local-level vaccine efficacy across the study area.

70 mune hemolytic anemia, and suspected lack of vaccine efficacy after dose 3 leading to pneumococcal in

71 e according-to-protocol cohort for efficacy, vaccine efficacy against 6-month persistent infection or

72 The primary endpoint was vaccine efficacy against 6-month persistent infection or

73 The primary endpoint was vaccine efficacy against 6-month persistent infection or

74 We also noted significant cross-protective vaccine efficacy against 6-month persistent infection wi

75 This is the first demonstration of vaccine efficacy against aerosol challenge with virulent

76 The observed vaccine efficacy against asymptomatic dengue virus infec

77 Vaccine efficacy against atypical squamous cells of unde

78 In the total vaccinated cohort, vaccine efficacy against CIN1+ irrespective of HPV was s

79 Studies of pneumococcal vaccine efficacy against colonization have been proposed

80 s within the circumsporozoite protein had on vaccine efficacy against first episodes of clinical mala

81 ossesses a bovine genetic backbone, the high vaccine efficacy against G8 strains might be partially e

82 Overall vaccine efficacy against herpes zoster was 97.2% (95% co

83 Vaccine efficacy against hospitalization for dengue was

84 PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, ce

85 Vaccine efficacy against HPV 16/18-related 6-month persi

86 Vaccine efficacy against HPV 16/18-related cytological a

87 Vaccine efficacy against HPV-31/33/45 for two-dose women

88 Vaccine efficacy against incident HPV-16/18 infection fo

89 We assessed vaccine efficacy against incident HPV-16/18 infection in

90 Vaccine efficacy against incident HPV-16/18 infections f

91 Vaccine efficacy against incident HPV-31/33/45 infection

92 We assessed two coprimary objectives: vaccine efficacy against laboratory-confirmed influenza

93 However, the immune responses necessary for vaccine efficacy against M. tuberculosis have not been d

94 s IFN-gamma and TNF is not a requirement for vaccine efficacy against M. tuberculosis, despite these

95 Secondary outcomes were immunogenicity and vaccine efficacy against Mycobacterium tuberculosis infe

96 Secondary analyses included vaccine efficacy against non-vaccine oncogenic HPV types

97 her than an M1, response may further improve vaccine efficacy against ocular HSV-1 replication and la

98 (for the HPV-16/18 endpoint), we calculated vaccine efficacy against one-time detection of incident

99 are increasing in incidence among males, and vaccine efficacy against oral HPV infections in men has

100 of protein per dose) to compare the relative vaccine efficacy against reverse-transcriptase polymeras

101 person-years in those in the placebo group; vaccine efficacy against severe rotavirus gastroenteriti

102 The primary outcome was vaccine efficacy against symptomatic, virologically conf

103 Vaccine efficacy against viruses with a lysine residue a

104 Many studies have documented lower vaccine efficacy among children in low-income countries,

105 s of simulated trial data, across a range of vaccine efficacies and trial start dates.

106 e the potential to be targeted for enhancing vaccine efficacy and antitumor immunity.

107 However, vaccine efficacy and direct effectiveness estimates have

108 that: the best-fitting model is one in which vaccine efficacy and duration of protection of the acell

109 Focusing on studies of vaccine efficacy and effectiveness in emergencies, we hi

110 se of BCG challenge as a tool for evaluating vaccine efficacy and identifying mechanisms of antimycob

111 Both direct vaccine efficacy and indirect herd protection contribute

112 f delay in vaccine introduction with limited vaccine efficacy and limited supplies are not unlikely i

113 Vaccine efficacy and pathogenesis studies for EV71 have

114 expressing P. vivax TRAP to allow studies of vaccine efficacy and protective mechanisms in rodents.

115 5-NA, could improve seasonal influenza virus vaccine efficacy and provide protection against emerging

116 In order to increase the vaccine efficacy and reduce the antigen dose, there is a

117 onses to infectious diseases and to increase vaccine efficacy and safety in aging individuals.

118 bisco((R))-100 and CoVaccineHT(TM), enhanced vaccine efficacy and sterile protection following malari

119 okine production that can be used to promote vaccine efficacy and the treatment of infections and mal

120 y is an important goal that seeks to improve vaccine efficacy and ultimately prevent infections that

121 HIV] were halted for futility due to lack of vaccine efficacy and unexpected excess HIV infections in

122 Sensitivity analysis for vaccine compliance, vaccine efficacy and vaccine start date was also conduct

123 almonella enterica serovar Stanleyville (91% vaccine efficacy), and S. Enteritidis CVD 1944 protected

124 ty analyses by varying vaccination coverage, vaccine efficacy, and duration of protection.

125 fy an immunization program's performance and vaccine efficacy, and guide polio eradication strategy.

126 The vaccine efficacy, as assessed by negative binomial regre

127 The vaccine efficacy based on the hazard ratio was 62.7% (95

128 ters for infection, case fatality rates, and vaccine efficacy, basic childhood vaccinations have been

129 n subject-specific response to infection and vaccine efficacy, but little is known about the role of

130 st that PD-1 blockade enhances breast cancer vaccine efficacy by altering both CD8 T cell and DC comp

131 m of CD4(+) T-cell responses that compromise vaccine efficacy by creating excess cellular targets of

132 tions for Tfr cell biology and for improving vaccine efficacy by formulating vaccines that modify the

133 We aimed to enhance vaccine efficacy by generating a more immunogenic CSP-ba

134 re was no evidence of effect modification of vaccine efficacy by precipitation (89% power).

135 Vaccine efficacy can be assessed in human subjects who h

136 during primary M. tuberculosis infection and vaccine efficacy, confirming the hypothesis that subdomi

137 e to the main study hospital and local-level vaccine efficacy, controlling for ecological factors, us

138 Vaccine efficacy correlated with serum neutralizing anti

139 antibody-enhanced infection and suggest that vaccine efficacy could be improved by exploiting cross-r

140 The principal stratification vaccine efficacy curve framework for statistically evalu

141 Estimates of vaccine efficacy decreased over time in the LTPS populat

142 ring self-limited infection that may help in vaccine efficacy definition, and in identifying possible

143 The significant vaccine efficacy documented 10 days and 3 months after 1

144 T cells and CD8alpha(+) DCs does not reduce vaccine efficacy, either directly or indirectly, in chal

145 Substudy (STPS) demonstrated persistence of vaccine efficacy for at least 5 years.

146 Statistically significant vaccine efficacy for HZ BOI persisted into year 10 postv

147 ccination, whereas statistically significant vaccine efficacy for incidence of HZ persisted only thro

148 ero through year 10 postvaccination, whereas vaccine efficacy for incidence of HZ was significantly g

149 l-predicted 13-valent pneumococcal conjugate vaccine efficacy for preventing vaccine-type specific CA

150 Vaccine efficacy for the HZ BOI was significantly greate

151 transmissibility and 5-fold fractional-dose vaccine efficacy for two vaccination scenarios, ie, rand

152 However, to date, limited vaccine efficacy has been reported and none have been li

153 The impact of the capsule on vaccine efficacy has not been explored.

154 with the right animal models for evaluating vaccine efficacy, has the potential to revolutionize vac

155 of protection from severe dengue disease and vaccine efficacy have not yet been established.

156 The estimated vaccine efficacy here was 100% (95% CI 79.3-100.0, p=0.0

157 ge with pathogenic SIVmac251, resulting in a vaccine efficacy (i.e., risk reduction per exposure) of

158 4 trial was held contributed to the observed vaccine efficacy.IMPORTANCE HIV-1-infected cells present

159 y has significant implications for improving vaccine efficacies in young children, the elderly, and i

160 Vaccine efficacy in adults who were 70 years of age or o

161 eukocytes (PBLs) represent a means to bridge vaccine efficacy in animal models to that in humans.

162 aim of the study was to ascertain HPV-16/18 vaccine efficacy in both full and naive cohorts and to e

163 ns per year, with worse outcomes and reduced vaccine efficacy in developing countries.

164 Despite greater vaccine efficacy in females, both young and older female

165 aboratories that assessed immunogenicity and vaccine efficacy in herpes simplex virus 1 (HSV-1)-serop

166 Vaccine efficacy in HIV-uninfected women was similar for

167 y trial represents the only example of HIV-1 vaccine efficacy in humans to date.

168 es to V2 are also important hallmarks of HIV-vaccine efficacy in humans will require further studies.

169 5, suggesting natural Ad5 exposure may limit vaccine efficacy in humans.

170 epartum (intention-to-treat population), and vaccine efficacy in infants born to women immunised at l

171 hanisms, providing the rationales to improve vaccine efficacy in infants, the elderly, immunocompromi

172 Compared to SPS, estimated vaccine efficacy in LTPS decreased from 61.1% to 37.3% f

173 However, tuberculosis vaccine efficacy in mice is critically dependent on the

174 The fusion construct was tested for vaccine efficacy in mouse models of nasopharyngeal carri

175 Vaccine efficacy in northern states was estimated to be

176 ides a plausible explanation for the reduced vaccine efficacy in populations with a high percentage o

177 mptive vaccine updates may improve influenza vaccine efficacy in previously exposed individuals.

178 osition 181 which was highly correlated with vaccine efficacy in RV144.

179 tudy (LTPS) was undertaken to further assess vaccine efficacy in SPS vaccine recipients followed for

180 nst serotype 6E, genetic variants may reduce vaccine efficacy in the longer term because of the emerg

181 The overall vaccine efficacy in this age category will depend on the

182 ge dose may be a critical factor in limiting vaccine efficacy in this model.

183 ntrol groups in two phase 3 trials of dengue vaccine efficacy included two large regional cohorts tha

184 For the primary study endpoint vaccine efficacy increased with distance from the main s

185 ain study hospital was positively related to vaccine efficacy, increasing at a rate of 4.5% per kilom

186 Rotavirus vaccine efficacy is lower in low-income countries than i

187 age in girls and boys is reached and if high vaccine efficacy is maintained over time.

188 hen perfect matches are achieved, suboptimal vaccine efficacy leaves several high-risk populations vu

189 ce from experimental infection suggests that vaccine efficacy may be affected by parasite-induced imm

190 influenza vaccination, raising concerns that vaccine efficacy might wane.

191 f 35 participants in the Vi-PS group to give vaccine efficacies of 54.6% (95% CI 26.8-71.8) for Vi-TT

192 l model to study transmission, diseases, and vaccine efficacies of respiratory viruses because of the

193 nd 105 (18%) of placebo recipients, giving a vaccine efficacy of 0.0% (95% CI -26.4 to 20.9).

194 virus disease from seven clusters, showing a vaccine efficacy of 100% (95% CI 74.7-100.0; p=0.0036).

195 40 (23%) of 173 in the placebo group, for a vaccine efficacy of 11.7% (95% CI -41.3 to 44.9).

196 1 vaccine clinical trial showed an estimated vaccine efficacy of 31.2%.

197 ne (3%) occurred in the placebo group, for a vaccine efficacy of 32.8% (95% CI -111.5 to 80.3).

198 converted between months 13 and 25, giving a vaccine efficacy of 33.5% (95% confidence interval [CI],

199 nts (6.0 [95% CI, 4.3-8.5]; 33 cases) with a vaccine efficacy of 43.1% (P = .050).

200 ce rate ratio, 0.43 [95% CI, .19-.93]) for a vaccine efficacy of 57.5% (P = .032).

201 n-years at risk) in the control group, for a vaccine efficacy of 60.8% (95% confidence interval [CI],

202 s per 100 person-years, respectively), for a vaccine efficacy of 66.7% (95% confidence interval [CI],

203 intention-to-treat analyses, which showed a vaccine efficacy of 69.1% (95% CI, 55.0 to 78.7).

204 -Pasteur formulations) yielded an overall aP vaccine efficacy of 84% (95% confidence interval [CI], 8

205 the vaccine group, for an intention-to-treat vaccine efficacy of 95.5%.

206 clades of HPAI A(H5) viruses in Vietnam, the vaccine efficacy of bivalent poultry vaccine formulation

207 Vaccine efficacy of LAIV for vaccine-matched strains was

208 for elucidating the biological function and vaccine efficacy of NadA.

209 the mechanisms responsible for the superior vaccine efficacy of rBCG are still incompletely understo

210 The utility of serologic testing to evaluate vaccine efficacy of seasonal inactivated influenza vacci

211 ne is lower than that of the whole-cell (wP) vaccine, (efficacy of the first three doses 80% [95% CI:

212 mphoid sites, which could be used to enhance vaccine efficacy or adoptive cell therapy treatments tha

213 f published studies that evaluated pertussis vaccine efficacy or effectiveness within 3 years after c

214 if these immune responses are predictors of vaccine efficacy or markers of natural resistance to HIV

215 ials of RotaTeqTM in Sub-Saharan Africa, the vaccine efficacy over a 2-year follow-up was lower again

216 Given waning vaccine efficacy over time, this secondary analysis demo

217 nderstanding antigenic evolution and informs vaccine efficacy predictions based on the genetic sequen

218 d the rate for IIV3 recipients was 7.0%; the vaccine-efficacy rate for these IIV3 recipients was 57.7

219 % and 1.9%, respectively, and the respective vaccine-efficacy rates were 50.4% (95% confidence interv

220 G-CSF) concentrations correlated strongly to vaccine efficacy regardless of adjuvant type.

221 uding glioblastoma, the factors dictating DC vaccine efficacy remain poorly understood.

222 Vaccine efficacy remained robust during the first 4 mont

223 Meta-analysis of 2 aP vaccine efficacy studies (assessing the 3-component Glax

224 Cost-effectiveness and vaccine efficacy studies are needed to evaluate the valu

225 of the mouse strains used when interpreting vaccine efficacy studies in animal models of malaria inf

226 limitations of using surrogate endpoints for vaccine efficacy studies of mid-adult women to guide pol

227 y therefore be better suited for preclinical vaccine efficacy studies.

228 ions to influenza vaccines, and show greater vaccine efficacy than males.

229 er but biologically important differences in vaccine efficacy that can influence future vaccine devel

230 he lack of a role for CD8alpha(+) T cells in vaccine efficacy, they in turn point to a role for GM-CS

231 s Prevention Study (SPS) demonstrated zoster vaccine efficacy through 4 years postvaccination.

232 xpected value of resolving uncertainty about vaccine efficacy, time delay to immunity after vaccinati

233 int was for the lower bound of the 95% CI of vaccine efficacy to be greater than 25%.

234 Vaccine efficacy to eliminate colonisation could also be

235 lications for antiviral drug susceptibility, vaccine efficacy, transmissibility and pathogenicity stu

236 udies on EV71 antiviral drug susceptibility, vaccine efficacy, transmissibility, and pathogenesis.

237 in a randomized controlled preventive HIV-1 vaccine efficacy trial can help elucidate mechanisms of

238 Furthermore, immune correlates in the RV144 vaccine efficacy trial generated the hypothesis that V1V

239 We analysed data from a reported vaccine efficacy trial of the tuberculosis vaccine MVA85

240 Despite these advances, a promising HIV-1 vaccine efficacy trial published in 2013 did not prevent

241 ce: The Thai RV144 ALVAC/AIDSVax prime-boost vaccine efficacy trial represents the only example of HI

242 tes of protection/immunity' in the RV144 HIV vaccine efficacy trial that are missed by other methods.

243 rrelate of decreased HIV-1 risk in the RV144 vaccine efficacy trial, suggesting that protection might

244 HIV Vaccine Trials Network (HVTN) 505 HIV-1 vaccine efficacy trial.

245 of the partially efficacious Thai RV144 HIV vaccine efficacy trial.

246 y B cells in RMs as observed in the HVTN 505 vaccine efficacy trial.

247 of breakthrough infection genomes in general vaccine efficacy trials for diverse pathogens.

248 Human HIV vaccine efficacy trials have not generated meaningful ne

249 orm selection of clinical end points for RSV vaccine efficacy trials.

250 essing immune response biomarkers as CoPs in vaccine efficacy trials.

251 ses performed on four major preventive HIV-1 vaccine efficacy trials: (i) the HIV Vaccine Trial Netwo

252 Ongoing strategies to improve vaccine efficacy typically focus on providing broad-spec

253 ody titres and the magnitude and duration of vaccine efficacy using data from a phase 3 trial done be

254 enge model is suitable for the assessment of vaccine efficacy using endpoints that include bacteremia

255 We estimated vaccine efficacy using pooled data from the first 25 mon

256 lts (PATRICIA), reported a 22% difference in vaccine efficacy (VE) against cervical intraepithelial n

257 Vaccine efficacy (VE) against vulvar human papillomaviru

258 cine and placebo groups, respectively, for a vaccine efficacy (VE) of -7.1% (90% confidence interval

259 The vaccine efficacy (VE) of 1 or 2 doses of AS03-adjuvanted

260 icacy of a vaccine regimen with an estimated vaccine efficacy (VE) of 31% for protecting low-risk Tha

261 hase III RV144 HIV-1 vaccine trial estimated vaccine efficacy (VE) to be 31.2%.

262 in 50-59-year-olds showed approximately 70% vaccine efficacy (VE) to reduce the incidence of herpes

263 ition selection pressure, we also found that vaccine efficacy (VE) was greater in A*02-positive (A*02

264 the effect of Y1 vaccination on Y2 relative vaccine efficacy (VE), immunogenicity (hemagglutination

265 ssess high-risk HPV variant lineage-specific vaccine efficacy (VE).

266 enabled virus genotype-specific estimates of vaccine efficacy (VE).

267 Time-varying vaccine efficacy (VE[t]) was examined in healthy adult p

268 al of 26 of 30 subjects in the Fx017M group (vaccine efficacy [VE], 86.7% [95% confidence interval [C

269 Vaccine efficacy waned over time (P=0.006 for the intera

270 The hazard ratio for vaccine efficacy was 0.517 (95% CI 0.313-0.856) by time-

271 Vaccine efficacy was 100% (95% CI 68.9-100.0, p=0.0045),

272 ntention-to-treat population, overall infant vaccine efficacy was 33.1% (95% CI 3.7-53.9); in the per

273 I 3.7-53.9); in the per-protocol population, vaccine efficacy was 37.3% (7.6-57.8).

274 5 to 17 months of age, the 1-year cumulative vaccine efficacy was 50.3% (95% confidence interval [CI]

275 Serotype-specific vaccine efficacy was 50.3% for serotype 1, 42.3% for ser

276 (those who received at least one injection), vaccine efficacy was 64.7% (95% CI, 58.7 to 69.8).

277 Vaccine efficacy was also estimated separately for north

278 The association between RAS activation and vaccine efficacy was also observed in an independent eff

279 After 7 months, vaccine efficacy was assessed by enumerating the M. lepr

280 Vaccine efficacy was assessed in a skin challenge and in

281 Vaccine efficacy was associated with alum-induced, but n

282 Vaccine efficacy was between 96.6% and 97.9% for all age

283 Vaccine efficacy was defined as 1 minus the hazard ratio

284 Vaccine efficacy was determined using a case-control stu

285 No statistically significant vaccine efficacy was found against the non-laboratory-co

286 isition T-cell selection, we also found that vaccine efficacy was greater for participants who expres

287 parasites expressing both PfUIS3 and PfTRAP, vaccine efficacy was improved to 100% sterile protection

288 mens tested here were extremely immunogenic, vaccine efficacy was limited to a modest reduction in se

289 After challenge with SIVmac239, vaccine efficacy was limited to a modest reduction in se

290 Vaccine efficacy was marginally higher in subjects aged

291 Protective vaccine efficacy was observed in 14 of 17 subjects (82.4

292 Also, vaccine efficacy was similar for PCR-CI (61.2%; 95% CI,

293 Although vaccine efficacy was similar when measured for PCR-CI or

294 We investigated whether the vaccine efficacy was specific to certain parasite genoty

295 Vaccine efficacy was sustained for up to 6 years.

296 itude of 6OXY-specific B cell activation and vaccine efficacy was tightly correlated to the size of t

297 nce high antibody titers are required for AD vaccine efficacy, we have decided to generate vaccines,

298 Safety and vaccine efficacy were evaluated using a guinea pig cytom

299 vaccine regimen demonstrated only a trend in vaccine efficacy, whereas the monomeric gp120 regimen si

300 Studies to confirm these findings and assess vaccine efficacy will now move to populations in regions